

ABSTRACT OF THE DISCLOSURE

~~A method is disclosed for inhibiting the action of TNF for treating neurological~~
conditions in a human by administering a TNF antagonist for reducing the inflammation
of neuronal tissue or the neuromuscular junction of a human, or for modulating the
immune response affecting neuronal tissue or the neuromuscular junction of a human by
5 administering to the human a therapeutically effective dosage level of a TNF antagonist.
The TNF antagonist is selected from the group consisting of etanercept, infliximab,
pegylated soluble TNF receptor Type I (PEGsTNF-R1), other agents containing soluble
10 TNF receptors, CDP571 (a humanized monoclonal anti-TNF-alpha antibody), other
monoclonal anti-TNF-alpha antibodies, TNF-alpha converting enzyme inhibitors and
D2E7 (a human anti-TNF mAb) for reducing the inflammation of neuronal tissue or the
neuromuscular junction of a human, or for modulating the immune response affecting
neuronal tissue or the neuromuscular junction of a human. Additionally, other TNF
15 antagonists are used for administering a therapeutically effective dosage level to a human
wherein the TNF antagonist is selected from the group consisting of thalidomide,
phosphodiesterase 4 (IV) inhibitor thalidomide analogues and other phosphodiesterase IV
inhibitors for reducing the inflammation of neuronal tissue or the neuromuscular junction
of a human, or for modulating the immune response affecting neuronal tissue or the
20 neuromuscular junction of a human.

ADP
u/15/10/

A method is disclosed for inhibiting the action of TNF for treating conditions of the optic nerve or retina in a human by administering a TNF antagonist for reducing the inflammation of the optic nerve or retina of a human, or for modulating the immune response affecting the optic nerve or retina of a human by administering a therapeutically effective dosage level to the human of a TNF antagonist. The TNF antagonist is selected from the aforementioned pharmacological products listed above.

ABSTRACT

A method is disclosed for inhibiting the action of TNF for treating muscular diseases in a human by administering a TNF antagonist for reducing the inflammation of muscle of a human, or for modulating the immune response affecting the muscle of a human by administering a therapeutically effective dosage level to the human of a TNF antagonist. The TNF antagonist is selected from the aforementioned pharmacological products listed above.

In the step of administering the TNF antagonist to a human, the TNF antagonist is performed through any of the following routes including subcutaneous, intravenous, intrathecal, intramuscular, intranasal, oral, transepidermal, parenteral, by inhalation, or intracerebroventricular.